Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2007

Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45(1):42-52.

A Crowson N, Magro C, Mihm MC. Unusual histologic and clinical variants of melanoma: implications for therapy. Curr Oncol Rep. 2007;9(5):403-10.

Baumgart E, Cohen MS, Neto BS, Jacobs MA, Wotkowicz C, Rieger-Christ KM, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res. 2007;13(6):1685-94.

Setlur SR, Royce TE, Sboner A, Mosquera J-, Demichelis F, Hofer MD, et al. Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res. 2007;67(21):10296-303.

Arora N, Hill C, Hoda SA, Rosenblatt R, Pigalarga R, Tousimis EA. Clinicopathologic features of papillary lesions on core needle biopsy of the breast predictive of malignancy. Am J Surg. 2007;194(4):444-9.

Chiu A, Xu W, He B, Dillon SR, Gross JA, Sievers E, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood. 2007;109(2):729-39.

Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell. 2007;12(2):160-70.

Zapata M, Cohen C, Siddiqui MT. Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: Utility and potential role. Cytojournal. 2007;4:13.

Rheault MN, van Burik J-, Mauer M, Ingulli E, Ferrieri P, Jessurun J, et al. Cat-scratch disease relapse in a kidney transplant recipient. Pediatr Transplant. 2007;11(1):105-9.

Heymann JJ, Benson MC, O'Toole KM, Malyszko B, Brody R, Vecchio D, et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol. 2007;25(1):77-84.